Bausch + Lomb (BLCO) Q2 2026 earnings review
Operating Leverage Shines as Surgical Segment Roars Back
Bausch + Lomb delivered a decisive beat-and-raise in Q2, proving that its 'Vision 27' margin expansion initiative is generating real leverage. Total revenue grew 9% reported (8% constant currency), while Adjusted EBITDA surged 26%. The standout was the Surgical segment, which abruptly reversed a multi-quarter trend of anemic 1% growth to deliver 16% constant currency growth, fueled by a massive 175% spike in premium IOLs. This broad-based performance and stellar cash flow conversion ($153M in operating cash flow vs $35M a year ago) prompted management to raise full-year revenue and profitability guidance. However, lingering GAAP net losses and a slight clinical miss in the enVista Beyond pipeline remain points for monitoring.
🐂 Bull Case
The Surgical business successfully absorbed past recall disruptions and field-force realignments. A 175% reported revenue surge in premium IOLs demonstrates strong competitive positioning and favorable mix shift.
Adjusted EBITDA is consistently growing at multiple times the rate of revenue. Operating income flipped from a $11M loss in 25Q2 to an $83M profit in 26Q2, driving massive cash flow improvements.
🐻 Bear Case
The pivotal study for the investigational enVista Beyond IOL missed predefined targets related to depth of focus and intermediate visual performance, introducing regulatory and commercial uncertainty.
Despite stellar non-GAAP metrics, the company still posted a $14M GAAP net loss, weighed down by debt refinancing fees and amortization, highlighting ongoing capital structure friction.
⚖️ Verdict: 🟢
Bullish. Management is executing flawlessly on their stated goals: accelerating revenue, expanding margins, and converting profits into cash. The Surgical segment's recovery removes a major previous overhang.
Key Themes
Surgical Segment Renaissance
Accelerating. After hovering around 1% constant currency growth for four quarters due to the enVista recall and field-force resets, Surgical revenue exploded to 16% CC growth in 26Q2 ($256M). The primary catalyst was a 175% reported growth in premium intraocular lenses (IOLs). Premium products now represent 13% of total Surgical revenue, up from 6% a year ago, providing a massive tailwind for future gross margins.
Dry Eye Engine Reaches Sustained Orbit
Stable. The Pharmaceuticals segment grew 14% CC, driven primarily by the transition of the dry eye portfolio from a 'launch' to a 'growth and profitability' phase. MIEBO and XIIDRA delivered a combined 27% revenue growth in the first half of 2026. This proves the company can successfully digest and scale the XIIDRA acquisition while maintaining MIEBO's blockbuster trajectory.
Vision 27 Efficiency Taking Root
Accelerating. Bausch + Lomb's focus on 'Financial Excellence' is translating directly to the bottom line. Operating income improved by $94M year-over-year. By stripping out acquired IPR&D, Adjusted EBITDA hit $246M, a 28% jump. The company is actively proving it can control SG&A and drive favorable product mix (like premium IOLs and Daily SiHy lenses) to expand margins.
enVista Beyond Clinical Trial Nuances
A specific data point contradicts the flawless innovation narrative. While the enVista Beyond investigational IOL met co-primary effectiveness endpoints, management disclosed it 'narrowly missing predefined performance targets related to depth of focus and intermediate visual performance.' While safety was excellent, missing these functional vision targets could complicate FDA submission or dampen competitive marketing claims upon launch.
Debt Refinancing Drag on Net Income
Stable. Bausch + Lomb remains unprofitable on a GAAP basis, posting a $14M net loss. While this is a $48M improvement from last year, the loss was primarily driven by financing fees stemming from a June 2026 debt refinancing transaction. Capital structure costs continue to obscure the underlying operational strength.
Tariff and Macro Policy Exposure
Management explicitly stated that the raised 2026 guidance 'does not take into consideration any changes in tariff policy, given the dynamic nature of the situation.' Furthermore, the company highlighted risks related to the 'One Big Beautiful Bill Act' impacting tax provisions. Any sudden geopolitical shifts or retaliatory trade measures remain unpriced risks to the current outlook.
Other KPIs
Accelerating. Cash flow from operations more than quadrupled compared to $35 million in 25Q2. This $118 million favorable change proves that the company's non-GAAP earnings improvements are converting into tangible cash generation, driven by higher revenue and operating efficiencies.
Stable. The segment delivered 4% constant currency growth, exactly matching its 25Q2 performance. Growth was powered by the daily SiHy portfolio, Biotrue ONEday, ULTRA monthly, and a +12% reported revenue boost from the newly launched Blink Triple Care Preservative Free franchise.
Guidance
Accelerating. Management raised the range from the previous $5.42B - $5.52B. The new midpoint ($5.49B) implies roughly 6.7% reported YoY growth. On a constant currency basis, the growth expectation was raised to 5.8% - 7.7%, reflecting stronger underlying business performance moving into H2.
Accelerating. Raised from the previous range of $1.01B - $1.06B. The midpoint ($1.05B) implies robust ~18% growth over FY25's $891M, confirming that the operating leverage demonstrated in H1 is expected to persist through the end of the year.
Key Questions
enVista Beyond Regulatory Path
Given that enVista Beyond narrowly missed its predefined targets for depth of focus and intermediate visual performance, what specifically needs to be negotiated with regulatory authorities, and does this alter the anticipated launch timeline?
Capital Allocation and Debt
With operating cash flow surging to $153M this quarter, how does this alter your timeline for deleveraging the balance sheet, and what are the remaining financial milestones required before parent company BHC can execute the separation?
Tariff Mitigation Readiness
Guidance explicitly excludes potential new tariff policies. If sweeping tariffs are enacted in H2 2026, what levers (pricing, supply chain shifts) are currently ready to deploy to protect the newly expanded EBITDA margins?